Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.
Also called NCT05098470
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose other
- Phase
- Phase 3
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT05098470
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05098470. Randomized; no masking; primary purpose other. Start 2022-03-07 (actual); primary completion 2025-07-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Insulin Glargine
- Intervention (Drug)
- Dorzagliatin
- Lead sponsor
- University of Alabama at Birmingham
- Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Record details
- Record id
cardio:ct-nct05098470- Content hash
734720d88b3563b691de579e2154ac49f72700b7bbb3f0ad04e562bb0db791ee